• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于非小细胞肺癌（NSCLC）患者的铂类化疗药物的药物遗传学的荟萃分析。

Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients.

机构信息

Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China.

出版信息

PLoS One. 2012;7(6):e38150. doi: 10.1371/journal.pone.0038150. Epub 2012 Jun 26.

DOI:10.1371/journal.pone.0038150
PMID:22761669
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3383686/
Abstract

AIM

To determine the pharmacogenetics of platinum-based chemotherapy in Non Small Cell Lung Cancer (NSCLC) patients.

METHODS

Publications were selected from PubMed, Cochrane Library and ISI Web of Knowledge. A meta-analysis was conducted to determine the association between genetic polymorphisms and platinum-based chemotherapy by checking odds ratio (OR) and 95% confidence interval (CI).

RESULTS

Data were extracted from 24 publications, which included 11 polymorphisms in 8 genes for meta-analysis. MDR1 C3435T (OR = 1.97, 95% CI: 1.11-3.50, P = 0.02), G2677A/T (OR = 2.61, 95% CI: 1.44-4.74, P = 0.002) and GSTP1 A313G (OR = 0.32, 95% CI: 0.17-0.58, P = 0.0002) were significantly correlated with platinum-based chemotherapy in Asian NSCLC patients.

CONCLUSION

Attention should be paid to MDR1 C3435T, G2677A/T and GSTP1 A313G for personalized chemotherapy treatment for NSCLC patients in Asian population in the future.

摘要

目的

确定非小细胞肺癌（NSCLC）患者铂类化疗的药物遗传学。

方法

从 PubMed、Cochrane 图书馆和 ISI Web of Knowledge 中选择出版物。通过检查比值比（OR）和 95%置信区间（CI），进行荟萃分析以确定遗传多态性与基于铂类的化疗之间的关联。

结果

从 24 篇出版物中提取了数据，其中包括 8 个基因中的 11 个基因多态性进行荟萃分析。MDR1 C3435T（OR = 1.97，95%CI：1.11-3.50，P = 0.02）、G2677A/T（OR = 2.61，95%CI：1.44-4.74，P = 0.002）和 GSTP1 A313G（OR = 0.32，95%CI：0.17-0.58，P = 0.0002）与亚洲 NSCLC 患者的基于铂类化疗显著相关。

结论

未来应注意 MDR1 C3435T、G2677A/T 和 GSTP1 A313G，以便为亚洲人群中的 NSCLC 患者进行个体化化疗治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dcb/3383686/3c4858042db6/pone.0038150.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dcb/3383686/0ada01ae0afe/pone.0038150.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dcb/3383686/6c7f0f6b899d/pone.0038150.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dcb/3383686/e53486d37a14/pone.0038150.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dcb/3383686/1865a66c2df7/pone.0038150.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dcb/3383686/a1b13a3f5d4a/pone.0038150.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dcb/3383686/3c4858042db6/pone.0038150.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dcb/3383686/0ada01ae0afe/pone.0038150.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dcb/3383686/6c7f0f6b899d/pone.0038150.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dcb/3383686/e53486d37a14/pone.0038150.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dcb/3383686/1865a66c2df7/pone.0038150.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dcb/3383686/a1b13a3f5d4a/pone.0038150.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dcb/3383686/3c4858042db6/pone.0038150.g006.jpg

相似文献

1
Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients.基于非小细胞肺癌（NSCLC）患者的铂类化疗药物的药物遗传学的荟萃分析。
PLoS One. 2012;7(6):e38150. doi: 10.1371/journal.pone.0038150. Epub 2012 Jun 26.
2
Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.遗传多态性与非小细胞肺癌铂类化疗治疗结局：基于遗传流行病学研究的荟萃分析。
Sci Rep. 2017 Jul 17;7(1):5593. doi: 10.1038/s41598-017-05642-0.
3
The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients: a meta-analysis.谷胱甘肽S-转移酶P1基因A313G和谷胱甘肽S-转移酶M1基因缺失/存在多态性与非小细胞肺癌（NSCLC）患者铂类化疗治疗反应之间的关联：一项荟萃分析。
Tumour Biol. 2014 Jul;35(7):6791-9. doi: 10.1007/s13277-014-1866-4. Epub 2014 Apr 12.
4
A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer.一项关于 ERCC1/MDR1 多态性与晚期非小细胞肺癌患者铂类化疗敏感性的荟萃分析评价。
Chin Med J (Engl). 2012 Aug;125(16):2902-7.
5
Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis.ERCC1 C118T/C8092A 多态性和 MDR1 C3435T 预测晚期非小细胞肺癌铂类化疗的疗效：荟萃分析。
Arch Med Res. 2011 Jul;42(5):412-20. doi: 10.1016/j.arcmed.2011.07.008. Epub 2011 Aug 7.
6
Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer.遗传多态性作为非小细胞肺癌铂类化疗潜在的药物遗传学生物标志物。
Mol Biol Rep. 2024 Jan 13;51(1):102. doi: 10.1007/s11033-023-08915-2.
7
Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment.CASP7 多态性与含铂化疗治疗的非小细胞肺癌患者生存的关联。
Chest. 2012 Sep;142(3):680-689. doi: 10.1378/chest.11-2522.
8
Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.谷胱甘肽S-转移酶P1（GSTP1）和X线修复交叉互补蛋白1（XRCC1）基因多态性与晚期非小细胞肺癌患者铂类化疗临床结局的相关性
Int J Clin Exp Pathol. 2015 Apr 1;8(4):4113-9. eCollection 2015.
9
Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.ERCC1-C118T 和 -C8092A 多态性与接受铂类化疗的晚期非小细胞肺癌患者的肺癌风险和生存的关联：基于 39 份报告的汇总分析。
Gene. 2013 Sep 10;526(2):265-74. doi: 10.1016/j.gene.2013.05.021. Epub 2013 May 30.
10
Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy.新型 CD74 多态性与 NSCLC 患者铂类化疗后血液学毒性的关联。
Clin Lung Cancer. 2014 Jan;15(1):67-78.e12. doi: 10.1016/j.cllc.2013.08.006. Epub 2013 Nov 9.

引用本文的文献

1
Role of GSTM1 and GSTT1 Gene Polymorphisms on Lung Cancer Susceptibility and Effect on Platinum-Based Chemotherapy-Induced Toxicity in Bangladeshi Lung Cancer Patients.GSTM1和GSTT1基因多态性在孟加拉国肺癌患者肺癌易感性中的作用及对铂类化疗所致毒性的影响
J Cancer Epidemiol. 2024 Nov 20;2024:9194714. doi: 10.1155/jcep/9194714. eCollection 2024.
2
Prognostic Impact of Dihydropyrimidine Dehydrogenase Germline Variants in Unresectable Non-Small Cell Lung Cancer Patients Treated with Platin-Based Chemotherapy.胚系二氢嘧啶脱氢酶基因变异对接受铂类化疗的不可切除性非小细胞肺癌患者预后的影响。
Int J Mol Sci. 2023 Jun 7;24(12):9843. doi: 10.3390/ijms24129843.
3

本文引用的文献

1
Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients.XRCC3 和 XPD751 SNP 与晚期 NSCLC 患者铂类化疗疗效的相关性。
Clin Transl Oncol. 2012 Mar;14(3):207-13. doi: 10.1007/s12094-012-0785-3.
2
Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients.ERCC1基因变异在晚期非小细胞肺癌患者铂类化疗治疗反应中的药物遗传学作用
Tumour Biol. 2012 Jun;33(3):877-84. doi: 10.1007/s13277-011-0314-y. Epub 2012 Jan 17.
3
Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are associated with susceptibility and chemotherapy response in non-small-cell lung cancer patients.
Overweight and Obesity are Associated with Poorer Survival Among Patients with Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy.
超重和肥胖与接受铂类化疗的晚期非小细胞肺癌患者较差的生存率相关。
Int J Gen Med. 2023 Jan 6;16:85-93. doi: 10.2147/IJGM.S382577. eCollection 2023.
4
Genome-wide analysis identify novel germline genetic variations in influencing platinum-based chemotherapy response in non-small cell lung cancer.全基因组分析鉴定出影响非小细胞肺癌铂类化疗反应的新型种系基因变异。
Acta Pharm Sin B. 2022 Mar;12(3):1514-1522. doi: 10.1016/j.apsb.2021.10.007. Epub 2021 Oct 16.
5
Synergistic effects of olaparib combined with on the sensitivity of cisplatin in non-small cell lung cancer.奥拉帕利联合[未提及药物名称]对非小细胞肺癌顺铂敏感性的协同作用。
Oncol Lett. 2021 May;21(5):365. doi: 10.3892/ol.2021.12626. Epub 2021 Mar 10.
6
Pharmacogenomics to Predict Tumor Therapy Response: A Focus on ATP-Binding Cassette Transporters and Cytochromes P450.预测肿瘤治疗反应的药物基因组学：聚焦于ATP结合盒转运蛋白和细胞色素P450
J Pers Med. 2020 Aug 28;10(3):108. doi: 10.3390/jpm10030108.
7
Cytochrome P-450 Polymorphisms and Clinical Outcome in Patients with Non-Small Cell Lung Cancer.细胞色素P-450基因多态性与非小细胞肺癌患者的临床结局
Turk J Pharm Sci. 2017 Dec;14(3):319-323. doi: 10.4274/tjps.28291. Epub 2017 Nov 20.
8
The Identification of Admixture Patterns Could Refine Pharmacogenetic Counseling: Analysis of a Population-Based Sample in Mexico.混合模式的识别可优化药物遗传学咨询：对墨西哥一个基于人群的样本的分析。
Front Pharmacol. 2020 Apr 22;11:324. doi: 10.3389/fphar.2020.00324. eCollection 2020.
9
Loss of ZNF587B and SULF1 contributed to cisplatin resistance in ovarian cancer cell lines based on Genome-scale CRISPR/Cas9 screening.基于全基因组CRISPR/Cas9筛选，ZNF587B和SULF1的缺失导致卵巢癌细胞系对顺铂产生耐药性。
Am J Cancer Res. 2019 May 1;9(5):988-998. eCollection 2019.
10
SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand.单核苷酸多态性在预测化疗的临床疗效和毒性方面：在流沙中前行。
Oncotarget. 2018 May 18;9(38):25355-25382. doi: 10.18632/oncotarget.25256.
GSTM1、CYP1A1、CYP2E1 和 CYP2D6 基因多态性与非小细胞肺癌患者的易感性和化疗反应相关。
Lung. 2012 Feb;190(1):91-8. doi: 10.1007/s00408-011-9338-8. Epub 2011 Nov 23.
4
A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer.ERCC1 的 C118T 多态性与晚期非小细胞肺癌患者对顺铂化疗的反应。
J Cancer Res Clin Oncol. 2012 Feb;138(2):231-8. doi: 10.1007/s00432-011-1090-1. Epub 2011 Nov 20.
5
Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical application.多药耐药相关蛋白1（MRP1/ABCC1）多态性：从发现到临床应用
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Oct;36(10):927-38. doi: 10.3969/j.issn.1672-7347.2011.10.002.
6
Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients.谷胱甘肽 S-转移酶 P1 和 XRCC1 的遗传多态性：预测晚期非小细胞肺癌（NSCLC）患者铂类化疗的临床疗效。
Swiss Med Wkly. 2011 Oct 19;141:w13275. doi: 10.4414/smw.2011.13275. eCollection 2011.
7
Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis.ERCC1 C118T/C8092A 多态性和 MDR1 C3435T 预测晚期非小细胞肺癌铂类化疗的疗效：荟萃分析。
Arch Med Res. 2011 Jul;42(5):412-20. doi: 10.1016/j.arcmed.2011.07.008. Epub 2011 Aug 7.
8
Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy.预测肺癌铂类化疗患者顺铂细胞毒性与总生存期相关的遗传变异。
Clin Cancer Res. 2011 Sep 1;17(17):5801-11. doi: 10.1158/1078-0432.CCR-11-1133. Epub 2011 Jul 20.
9
ABCC1 polymorphism Arg723Gln (2168G> A) is associated with lung cancer susceptibility in a Chinese population.ABCC1 多态性 Arg723Gln（2168G> A）与中国人群肺癌易感性相关。
Clin Exp Pharmacol Physiol. 2011 Sep;38(9):632-7. doi: 10.1111/j.1440-1681.2011.05571.x.
10
Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.多种药物作用途径的遗传变异与化疗治疗晚期非小细胞肺癌患者的生存关系。
Clin Cancer Res. 2011 Jun 1;17(11):3830-40. doi: 10.1158/1078-0432.CCR-10-2877.